WallStreetZenWallStreetZen

NASDAQ: ATXS
Astria Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ATXS

Based on 3 analysts offering 12 month price targets for Astria Therapeutics Inc.
Min Forecast
$17.00+19.21%
Avg Forecast
$20.00+40.25%
Max Forecast
$25.00+75.32%

Should I buy or sell ATXS stock?

Based on 3 analysts offering ratings for Astria Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ATXS stock forecasts and price targets.

ATXS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-30
lockedlocked$00.00+00.00%2023-11-15
lockedlocked$00.00+00.00%2023-10-12

1 of 1

Forecast return on equity

Is ATXS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.53%

Forecast return on assets

Is ATXS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ATXS revenue forecast

What is ATXS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$5.0M
Avg 2 year Forecast
$172.7M
Avg 3 year Forecast
$62.7M

ATXS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATXS$14.26$20.00+40.25%Buy
MRNS$9.54$25.25+164.68%Strong Buy
LBPH$21.47$40.60+89.10%Strong Buy
VYGR$9.64$14.00+45.23%Strong Buy
AEON$13.72N/AN/A

Astria Therapeutics Stock Forecast FAQ

Is Astria Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ATXS) stock is to Buy ATXS stock.

Out of 3 analysts, 0 (0%) are recommending ATXS as a Strong Buy, 3 (100%) are recommending ATXS as a Buy, 0 (0%) are recommending ATXS as a Hold, 0 (0%) are recommending ATXS as a Sell, and 0 (0%) are recommending ATXS as a Strong Sell.

If you're new to stock investing, here's how to buy Astria Therapeutics stock.

What is ATXS's revenue growth forecast for 2026-2028?

(NASDAQ: ATXS) Astria Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Astria Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ATXS's revenue for 2026 to be $181,480,955, with the lowest ATXS revenue forecast at $181,480,955, and the highest ATXS revenue forecast at $181,480,955. On average, 2 Wall Street analysts forecast ATXS's revenue for 2027 to be $6,269,259,590, with the lowest ATXS revenue forecast at $540,813,246, and the highest ATXS revenue forecast at $11,997,705,935.

In 2028, ATXS is forecast to generate $2,273,956,366 in revenue, with the lowest revenue forecast at $1,157,848,493 and the highest revenue forecast at $3,390,064,239.

What is ATXS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ATXS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ATXS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ATXS price target, the average ATXS price target is $20.00, with the highest ATXS stock price forecast at $25.00 and the lowest ATXS stock price forecast at $17.00.

On average, Wall Street analysts predict that Astria Therapeutics's share price could reach $20.00 by Jan 30, 2025. The average Astria Therapeutics stock price prediction forecasts a potential upside of 40.25% from the current ATXS share price of $14.26.

What is ATXS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ATXS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.